Use of Mycophenolate Sodium in Stable Renal Transplant Recipients in Spain: Preliminary Results of the MIDATA Study

Transplantation Proceedings

Volumn 41, Issue 6, 2009, Pages 2309-2312

  Sanchez Fructuoso A ^a   Ruiz, J C ^b   Rengel, M ^c   Andres A ^d   Morales, J M ^d   Beneyto, I ^e   Guirado, L I ^f   Cantarell, C ^g  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e HOSPITAL UNIVERSITARIO LA FE   (Spain)

^f FUNDACIÓ PUIGVERT   (Spain)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN; MYCOPHENOLIC ACID; TACROLIMUS;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CREATININE CLEARANCE; DIARRHEA; DRUG TOLERABILITY; ENTERIC COATED TABLET; FEMALE; GASTROINTESTINAL SYMPTOM; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; SPAIN;

ADULT; CREATININE; GASTROINTESTINAL DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MIDDLE AGED; MYCOPHENOLIC ACID; SPAIN; TREATMENT OUTCOME;

EID: 68949212932     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2009.06.067     Document Type: Article

References (14)

1. Ciancio G., Miller J., and Gonwa T.A. Review of major clinical trials with mycophenolate mofetil in renal transplantation. Transplantation 80 2 suppl (2005) S191
2. Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management. Drug Saf 24 (2001) 645
3. Pelletier R.P., Akin B., Henry M.L., et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transpl 17 (2002) 200
4. Knoll G.A., MacDonald I., Khan A., et al. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 14 (2003) 2381
5. Hardinger K.L., Brennan D.C., Lowell J., et al. Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. Transpl Int 17 (2004) 609
6. Bunnapradist S., Lentine K.L., Burroughs T.E., et al. Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure. Transplantation 82 (2006) 102
7. Salvadori M., Holzer H., de Mattos A., et al., ERLB301 Study Group. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 4 (2004) 231
8. Budde K., Curtis J., Knoll G., et al., ERL B302 Study Group. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant 4 (2003) 237
9. Massari P., Duro-Garcia V., Giron F., et al. Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients. Transplant Proc 37 (2005) 916
10. Hardinger K.L., Hebbar S., Bloomer T., et al. Adverse drug reaction driven immunosuppressive drug manipulations: a single-center comparison of enteric-coated mycophenolate sodium vs. mycophenolate mofetil. Clin Transplant 22 (2008) 555
11. Pelletier R.P., Soule J., Henry M.L., et al. Clinical outcome of renal transplant recipients treated with enteric-coated mycophenolic acid vs. mycophenolate as a switch agent using a primary steroid-free rapamune and microemulsion cyclosporine protocol. Clin Transplant 21 (2007) 532
12. Chan L., Mulgaonkar S., Walker R., et al. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplantation 81 (2006) 1290
13. Budde K., Glander P., Kramer B.K., et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. Transplantation 83 (2007) 417
14. Budde K., Tedesco-Silva H., Pestana J.M., et al. Enteric-coated mycophenolate sodium provides higher mycophenolic acid predose levels compared with mycophenolate mofetil: implications for therapeutic drug monitoring. Ther Drug Monit 29 (2007) 381